Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,543 shares of the biopharmaceutical company’s stock after acquiring an additional 144 shares during the period. PNC Financial Services Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $3,450,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ALNY. Acadian Asset Management LLC raised its holdings in Alnylam Pharmaceuticals by 30.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 386 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in Alnylam Pharmaceuticals by 9.6% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 2,181 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 191 shares during the last quarter. UniSuper Management Pty Ltd raised its holdings in Alnylam Pharmaceuticals by 100.0% in the 1st quarter. UniSuper Management Pty Ltd now owns 1,800 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 900 shares during the last quarter. Natixis acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at about $102,000. Finally, Advisors Asset Management Inc. raised its holdings in Alnylam Pharmaceuticals by 194.0% in the 1st quarter. Advisors Asset Management Inc. now owns 4,037 shares of the biopharmaceutical company’s stock valued at $603,000 after acquiring an additional 2,664 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ALNY. Raymond James increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. TD Cowen increased their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 26th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $244.89 on Monday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market capitalization of $31.59 billion, a PE ratio of -93.47 and a beta of 0.39. The firm has a 50 day moving average of $273.13 and a two-hundred day moving average of $238.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the company earned $1.15 earnings per share. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.